Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.15)
# 491
Out of 4,893 analysts
61
Total ratings
53.49%
Success rate
15.09%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $12.62 | -28.68% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $38.47 | -14.22% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $134.00 | +41.79% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $102.40 | -2.34% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $20.72 | -8.30% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $353.28 | +10.39% | 4 | Mar 6, 2025 | |
| TEM Tempus AI | Downgrades: Neutral | $50 → $55 | $59.60 | -7.72% | 3 | Feb 25, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $55 | $51.29 | +7.23% | 1 | Feb 21, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $124.17 | +28.86% | 6 | Nov 26, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $650 → $670 | $430.73 | +55.55% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $80 | $74.53 | +7.35% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $5.50 | +263.97% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,236.24 | +13.25% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $12.08 | -50.33% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.50 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $43.58 | +106.52% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $205.51 | +31.38% | 4 | Dec 20, 2023 |
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $12.62
Upside: -28.68%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $38.47
Upside: -14.22%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $134.00
Upside: +41.79%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $102.40
Upside: -2.34%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $20.72
Upside: -8.30%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $353.28
Upside: +10.39%
Tempus AI
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $59.60
Upside: -7.72%
Guardant Health
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $51.29
Upside: +7.23%
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $124.17
Upside: +28.86%
Thermo Fisher Scientific
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $430.73
Upside: +55.55%
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $74.53
Upside: +7.35%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $5.50
Upside: +263.97%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,236.24
Upside: +13.25%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $12.08
Upside: -50.33%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.50
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $43.58
Upside: +106.52%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $205.51
Upside: +31.38%